Stock Events

Stock Events

Climb Bio 

$11.17
34
+$0.05+0.45% Tuesday 20:00

Statistics

Day High
11.33
Day Low
10.8
52W High
12.22
52W Low
1.17
Volume
304,624
Avg. Volume
-
Mkt Cap
761.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.31
-0.25
-0.19
-0.13
Expected EPS
-0.224014
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-147.79MNet Income

Analyst Ratings

19.1Average Price Target
The highest estimate is 25.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLYM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap28.56B
Biogen has a strong focus on neurological diseases, making it a direct competitor in the neurology space.
Alkermes
ALKS
Mkt Cap5.91B
Alkermes works on central nervous system (CNS) diseases, overlapping with Eliem's focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.84B
Acadia Pharmaceuticals specializes in CNS disorders, including treatments for neurological and psychiatric conditions.
AMGEN
AMGN
Mkt Cap179.12B
Amgen has a broad portfolio that includes treatments for neurological conditions, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap278.64B
Novartis offers a wide range of neurology and psychiatry medications, making it a competitor in Eliem's market.
Pfizer
PFE
Mkt Cap146.36B
Pfizer has a diversified portfolio that includes drugs for neurological conditions, directly competing with Eliem.
Lilly(Eli) &
LLY
Mkt Cap845.77B
Eli Lilly has a strong emphasis on neurodegenerative diseases and psychiatric disorders, areas of interest for Eliem.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap41.6B
Teva Pharmaceutical Industries has a focus on CNS treatments, including generic and specialty medicines that compete with Eliem.
Johnson & Johnson
JNJ
Mkt Cap532.77B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for neurological and mental health conditions, competing with Eliem.

About

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Show more...
CEO
Dr. Susan Altschuller M.B.A., Ph.D.
Employees
17
Country
United States
ISIN
US28658R1068

Listings

XNAS
US
CLYM
BOATS
BOATS
CLYM.BOATS

0 Comments

Share your thoughts

FAQ

What is Climb Bio stock price today?▼
The current price of CLYM is $11.17 USD — it has increased by +0.45% in the past 24 hours. Watch Climb Bio stock price performance more closely on the chart.
What is Climb Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Climb Bio stocks are traded under the ticker CLYM.
Is Climb Bio stock price growing?▼
CLYM stock has fallen by -8.59% compared to the previous week, the month change is a +29.43% rise, over the last year Climb Bio has showed a +779.53% increase.
What is Climb Bio market cap?▼
Today Climb Bio has the market capitalization of 761.62M
When is the next Climb Bio earnings date?▼
Climb Bio is going to release the next earnings report on August 18, 2026.
What were Climb Bio earnings last quarter?▼
CLYM earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.29 USD resulting in a +30.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Climb Bio revenue for the last year?▼
Climb Bio revenue for the last year amounts to 0 USD.
What is Climb Bio net income for the last year?▼
CLYM net income for the last year is -147.79M USD.
How many employees does Climb Bio have?▼
As of May 13, 2026, the company has 17 employees.
In which sector is Climb Bio located?▼
Climb Bio operates in the Health & Wellness sector.
When did Climb Bio complete a stock split?▼
Climb Bio has not had any recent stock splits.
Where is Climb Bio headquartered?▼
Climb Bio is headquartered in Wellesley Hills, United States.